ArticleNeuropsychiatry2014
Current electroconvulsive therapy practice and research in the geriatric population.
Article in Neuropsychiatry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04441008 (Radical aiTBS Protocol for Intractable Depression), which is not on this map. Cited by 38 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Radical aiTBS Protocol for Intractable Depression
Who cites it
38 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Efficacy of esketamine nasal spray for treatment-resistant depression: A meta-analysis of randomized controlled studies.Medicine · 2025Pooled it
- Beyond the surface: analyzing etomidate and propofol as anesthetic agents in electroconvulsive therapy-A systematic review and meta-analysis of seizure duration outcomes.Frontiers in neurology · 2023Pooled it
- Transcranial magnetic stimulation (TMS) for geriatric depression.Ageing research reviews · 2022Pooled it
- Pharmacological Re-Optimization With Venlafaxine in Two Elderly Patients With Severe Major Depressive Disorder Considered for Electroconvulsive Therapy: A Two-Patient Case Report.Clinical case reports · 2026Article
- Review and Update of Anesthetic Management for Electroconvulsive Therapy: A Narrative Review.Neuropsychiatric disease and treatment · 2026Review
- Electroconvulsive therapy modulates the interplay between depressive symptoms in difficult-to-treat depression: A longitudinal network analysis.European psychiatry : the journal of the Association of European Psychiatrists · 2025Article
- Safety of electroconvulsive therapy in the context of physiological and medical complexity: A state-of-the art review.PCN reports : psychiatry and clinical neurosciences · 2025Review
- Behavioral and Psychological Symptoms (BPSD) in Alzheimer's Disease (AD): Development and Treatment.Current topics in behavioral neurosciences · 2025Review
- How electroconvulsive therapy works in the treatment of depression: is it the seizure, the electricity, or both?Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Review
- A narrative review: suicide and suicidal behaviour in older adults.Frontiers in psychiatry · 2024Review
- Electroconvulsive therapy for the acute management of severe agitation in dementia (ECT-AD): A modified study protocol.PloS one · 2024Article
- Baseline levels of miR-223-3p correlate with the effectiveness of electroconvulsive therapy in patients with major depression.Translational psychiatry · 2023Article
- Rocuronium action can be affected by hyperventilation: a case report and computational simulation.Journal of clinical monitoring and computing · 2023Article
- Impact of modeled field of view in electroconvulsive therapy current flow simulations.Frontiers in psychiatry · 2023Article
- The Effects of Baseline Impaired Global Cognitive Function on the Efficacy and Cognitive Effects of Electroconvulsive Therapy in Geriatric Patients: A Retrospective Cohort Study.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2022Article
- Association between electroconvulsive therapy and depressive disorder from 2012 to 2021: Bibliometric analysis and global trends.Frontiers in human neuroscience · 2022Article
- Rivastigmine for ECT-induced cognitive adverse effects in late life depression (RECALL study): A multicenter, randomized, double blind, placebo-controlled, cross-over trial in patients with depression aged 55 years or older: Rationale, objectives and methods.Frontiers in psychiatry · 2022Article
- The ratio and interaction between neurotrophin and immune signaling during electroconvulsive therapy in late-life depression.Brain, behavior, & immunity - health · 2021Article
- Efficacy of electroconvulsive therapy as a potential first-choice treatment in treatment-resistant depression (Review).Experimental and therapeutic medicine · 2021Review
- A Narrative Overview of Current Anesthetic Drugs in Electroconvulsive Therapy.Life (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Electroconvulsive therapy (ECT) is utilized worldwide for various severe and treatment-resistant psychiatric disorders. Research studies have shown that ECT is the most effective and rapid treatment available for elderly patients with depression, bipolar disorder and psychosis. For patients who suffer from intractable catatonia and neuroleptic malignant syndrome, ECT can be life saving. For elderly patients who cannot tolerate or respond poorly to medications and who are at a high risk for drug-induced toxicity or toxic drug interactions, ECT is the safest treatment option. Organic causes are frequently associated with late-life onset of neuropsychiatric conditions, such as parkinsonism, dementia and stroke. ECT has proven to be efficacious even when these conditions are present. During the next decade, research studies should focus on the use of ECT as a synergistic therapy, to enhance other biological and psychological treatments, and prevent symptom relapse and recurrence.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.